CagriSema (the combination) was submitted for FDA approval in December 2025, but cagrilintide on its own is earlier in the process
This could be beneficial for people who need intensive or targeted glutathione therapy, such as those with specific medical conditions or treatment goals
Designed for dry, sensitive, and aging skin, it helps improve the look of dullness, rough texture, and fine lines while supporting a healthier-looking skin barrier
Treatment of the CB1 -/- mice with low-dose dexamethasone did not significantly suppress their corticosterone levels and surprisingly caused a paradoxical rise in ACTH levels when compared to the wild-type, although high-dose dexamethasone suppressed corticosterone and ACTH to the same degree in both CB1 -/- and CB1 +/+ mice
More human trials are needed to understand the potential of NAC in this capacity and examine the synergistic effect of NAC alongside pharmaceutical treatment